A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

被引：22
|
作者：
Watts, Justin M. [1 ]
Bradley, Terrence J. [1 ]
Thomassen, Amber [2 ]
Brunner, Andrew M. [3 ]
Minden, Mark D. [4 ]
Papadantonakis, Nikolaos [5 ]
Abedin, Sameem [6 ]
Baines, Amanda J. [7 ]
Barbash, Olena [8 ]
Gorman, Shelby [8 ]
Kremer, Brandon E. [8 ]
Borthakur, Gautam M. [9 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Sylvester Canc Ctr, Miami, FL USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hlth Network, Dept Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Taussig Canc Inst, Birmingham, AL USA
[6] Northwestern Mem Hosp, McGaw Med Ctr, Milwaukee, WI USA
[7] GlaxoSmithKline, Stevenage, Herts, England
[8] GlaxoSmithKline, Collegeville, PA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2656
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms
    Watts, Justin
    Minden, Mark D.
    Bachiashvili, Kimo
    Brunner, Andrew M.
    Abedin, Sameem
    Crossman, Timothy
    Zajac, Magdalena
    Moroz, Veronica
    Egger, Jacqueline L.
    Tarkar, Aarti
    Kremer, Brandon E.
    Barbash, Olena
    Borthakur, Gautam
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [2] METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
    Postel-Vinay, S.
    Italiano, A.
    Romano, P. Martin
    Cassier, P. A.
    Siu, L. L.
    Lossos, I. S.
    Hilton, J. F.
    Mckean, M. A.
    Strauss, J.
    Falchook, G. S.
    de Jonge, M. J. A.
    Opdam, F. L.
    Rasco, D.
    Vermaat, J. S.
    Crossman, T.
    Zajac, M.
    Hainline, A.
    Kremer, B.
    Barbash, O.
    Gounder, M. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S746 - S747
  • [3] METEOR-1: A phase I study GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
    Siu, L. L.
    Rasco, D. W.
    Vinay, S. Postel
    Romano, P. Martin
    Menis, J.
    Opdam, F. L.
    Heinhuis, K. M.
    Egger, J. L.
    Gorman, S. A.
    Parasrampuria, R.
    Wang, K.
    Kremer, B. E.
    Gounder, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 159 - 159
  • [4] A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma
    Rasco, Drew
    Tolcher, Anthony
    Siu, Lillian L.
    Heinhuis, Kimberley
    Postel-Vinay, Sophie
    Barbash, Olena
    Egger, Jacqueline L.
    Gorman, Shelby
    Horner, Thierry
    Dhar, Arindam
    Kremer, Brandon E.
    CANCER RESEARCH, 2017, 77
  • [5] Preclinical Activity of the Clinical Stage Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Splicing Mutant Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    Schwartz, Leya Y.
    Choudhary, Gaurav S.
    Ramachandra, Nandini
    Sahu, Srabani
    Gordon, Shanisha
    Ruggeri, Bruce
    Heiser, Diane
    Scherle, Peggy
    Starczynowski, Daniel
    Verma, Amit
    BLOOD, 2021, 138
  • [6] Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia
    Weihrauch, MR
    Staib, P
    Seiberlich, B
    Hoffmann, M
    Diehl, V
    Tesch, H
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 699 - 704
  • [7] Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia
    Lowenberg, Bob
    Morgan, Gareth
    Ossenkoppele, Gert J.
    Burnett, Alan K.
    Zachee, Pierre
    Duehrsen, Ulrich
    Dierickx, Daan
    Mueller-Tidow, Carsten
    Sonneveld, Pieter
    Krug, Utz
    Bone, Elisabeth
    Flores, Nicolas
    Richardson, Alison F.
    Hooftman, Leon
    Jenkins, Chris
    Zweegman, Sonja
    Davies, Faith
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) : 4333 - 4338
  • [8] A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia
    Muus, Petra
    Langemeijer, Saskia
    van Bijnen, Sandra
    Blijlevens, Nicole
    de Witte, Theo
    LEUKEMIA RESEARCH, 2021, 105
  • [9] A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Wilhelm, Francois
    Hearn, Katherine
    Odchimar-Reissig, Rosalie
    Demakos, Erin P.
    Alvarado, Yesid
    Daver, Naval
    DiNardo, Courtney D.
    Konopleva, Marina
    Borthakur, Gautam
    Azarnia, Nozar
    Silverman, Lewis R.
    BLOOD, 2014, 124 (21)
  • [10] Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Faderl, Stefan
    Ravandi, Farhad
    Westwood, Robert
    Green, Simon R.
    Chiao, Judy H.
    Boone, Patricia A.
    Cortes, Jorge
    Plunkett, William
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) : 285 - 291
12345